CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 140 enrolled
Drug / intervention
Tiotropium +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01727024
NCT01727024Phase 4Completed

Study to Evaluate the Preference, Satisfaction and Correct Use of Inhalers in Patients With Chronic Obstructive Pulmonary Disease

Novartis Pharmaceuticals·interventional·Posted Nov 15, 2012·Updated Jan 24, 2017

In Brief

A Phase 4 clinical trial evaluating Tiotropium and Indacaterol for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 140 participants across 10 sites.

Detailed Summary

This study compared the correct use of and patient preference for two drug delivery systems (inhalers) in patients with COPD

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBrazil
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 15, 2012
Enrollment StartApr 1, 2013
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 13.6 years ago

Interventions

Tiotropiumdrug

Tiotropium via Respimat® device once a day

Indacateroldrug

Indacaterol via Breezhaler® device once a day